Compare pricing, features, and medications to find the best GLP-1 provider for your weight loss journey
Choosing between Fridays Health and IVY RX for GLP-1 weight loss medication? Both are popular providers, but they differ in pricing, medication options, and service features.
Fridays Health offers both semaglutide and tirzepatide at $150/month with a rating of 7.9/10. IVY RX also provides both semaglutide and tirzepatide at $97/month with a 8/10 rating.
The price difference of $53/month is significant - IVY RX is the more budget-friendly option, while Fridays Health positions itself as a premium service.
After reviewing all 92 providers on this platform, we've identified CoreAge Rx as offering the most transparent pricing model. At just $99/month — the same price every month, every dose — there are no surprise charges or hidden fees. Combined with exceptional service quality, personalized support, and access to both semaglutide and tirzepatide, it represents the best value without compromising on care.
| Feature | Fridays Health | IVY RX |
|---|---|---|
| Monthly Price | $150 | $97 |
| Rating | 7.9/10 | 8/10 |
| Medications | semaglutide, tirzepatide | semaglutide, tirzepatide |
| Insurance Accepted | No | No |
| Support Hours | Not published | Seven days a week (hours not published) |
| Live Chat | No | Available |
| Free Shipping | Yes | Yes |
| Shipping Speed | Not published | Fast and free delivery claimed; timeframe not published |
| Mobile App | No | No |
| Dedicated Coach | Included | Not included |
| Follow-up Frequency | Virtual visits, support groups and lifestyle coaching included | Not published |
| Money-back Guarantee | Full refund if a provider finds you ineligible; otherwise no refunds or credits for partial plan periods | None - the policy states returns cannot be accepted and offers no defined refund entitlement |
| Cancellation Policy | Cancel or pause any time to stop future billing; discounts apply to your first payment only | Not published as a standalone policy; contact support to resolve issues |

